Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Status:

Recruiting

III

Phase

1st

Line of Therapy

Early Cancer

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Inotuzumab Ozogamicin

Antibody‒Drug Conjugate (i.v.)

Treatment Arms

o Experimental: Arm II (frontline chemotherapy, inotuzumab ozogamicin)

o Active Comparator: Arm I (frontline chemotherapy)